AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 APR 25 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - A prospective study of human immunodeficiency virus type 1 (HIV-1) incidence among high-risk cohorts lends support to the idea that HIV-1 vaccine trials would be appropriate and welcomed in these populations in the United States.
"Questions exist about whether testing of preventive HIV-1 vaccines, which will require rapid recruitment and retention of cohorts with high HIV-1 seroincidence, is feasible in the United States," said G.R. Seage, III, and colleagues in the HIVNET Vaccine Preparedness Study group at the Harvard School of Public Health.
They conducted a prospective cohort study in 1995-1997 among 4,892 people at high risk for HIV infection in nine U.S. cities.
Of the 88% of study participants responding, 90 had HIV-1 infection, for an overall rate of 1.31/100 person-years. Men who had sex with men were at greatest risk (1.55/100 person-years), followed by male intravenous (IV) drug users (0.38/100 person-years), female IV drug users (1.24/100 person-years), and heterosexual women (01.13/100 person-years), reported Seage et al.
Men who had sex with men who reported unprotected anal intercourse, participants who were definitely willing to enroll in an HIV vaccine trial, and women who used crack cocaine had the highest incidence of HIV ("Are U.S. populations appropriate for trials ...